HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ibandronate

HCID 60852
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
114084-78-5
Standard SMILES
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
Molecular formula
C9H23NO7P2
Average molar mass
319.23 g/mol
Monoisotopic mass
319.09497607

Overview

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid]. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA approval on 16 May 2003.

Names & identifiers

Preferred name
Ibandronate
IUPAC
[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
English name
Ibandronic acid
Molecular formula
C9H23NO7P2
Molecular weight
319.23

Names & synonyms

Ibandronic AcidIbandronate114084-78-5BondenzaIasibon{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acidIbandronic Acid TevaIbandronic Acid AccordIbandronic Acid Sandoz[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acidAcido ibandronicoacide ibandronique
Show more names
IbandronicBPH 24Ibadronic AcidIbandronate AcidIBANDRONIC ACID-D3Tirofiban Impurity 67Ibandronic acid USP/EP/BPIbandronic Acid (Ibandronate)[1-Hydroxy-3-(MethylpentylaMino)propylidene]diphosphonic Acid
UMD7G2653WNSC-722623DTXSID5048340RPR-102289AQuodixor(1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonic acidacidum ibandronicumRefChem:56785

Database identifiers

CAS

Properties

Computed structural properties

XLogP
-4.1
Topological polar surface area
139 Ų
Hydrogen bond donors
5
Hydrogen bond acceptors
8
Rotatable bonds
9
Heavy atoms
19
Formal charge
0
Complexity
342

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-2.1
Solubility · 2 items

Freely soluble

1.34e+01 g/L

Human Drugs · 6 items

Breast Feeding; Lactation; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Melting Point113-115
Physical DescriptionSolid
Collision Cross Section170.12 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (95.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 21 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (95.2%)

Toxicology

Exposure RoutesPoorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
Toxicity Summary · 1 item

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Chemistry & industry

Pharmacology

ATC Code · 2 items

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingIbandronate's protein binding in serum varies from 85.7-99.5% over a concentration of 0.5-10ng/mL, but is generally 86% across a concentration range of 20-2000ng/mL.
Pharmacodynamics · 1 item

Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women. The therapeutic index is wide as overdoses are not especially toxic, and the duration of action is long as the half life can be up to 157 hours. Patients should be counselled regarding the risk of upper GI adverse reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures of the femur, and severe renal impairment.

Mechanism of Action · 1 item

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. ibandronate also activated caspase-3 which contribute to apoptosis.

Biological Half-LifeThe half life of ibandronate in postmenopausal women ranges from 37-157 hours.
Metabolism/Metabolites · 2 items

Related reactions

36 records
New reaction record
HRID 229896 reaction equation
HRID 229896As reactant
HRID 229897 reaction equation
HRID 229897As reactant
HRID 229898 reaction equation
HRID 229898As reactant
HRID 229899 reaction equation
HRID 229899As reactant
HRID 229900 reaction equation
HRID 229900As reactant
HRID 229901 reaction equation
HRID 229901As reactant
HRID 229902 reaction equation
HRID 229902As reactant
HRID 229903 reaction equation
HRID 229903As reactant
PreviousPage 1 of 5

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
114084-78-5
PubChem CID
60852
DTXSID
DTXSID5048340
ChEMBL
CHEMBL997
UNII
UMD7G2653W
EC Number
688-095-0
Nikkaji
J476.066B
Melting point
113 · 113-115°C
Boiling point
587.8 · 587.8±60.0 °C(Predicted)
Density
1.449 · 1.449±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
solubility
Aqueous Base (Slightly), Methanol (Slightly), Water (Slightly)
pka
1.6 · 1.60±0.10(Predicted)
form
Solid
color
White to Off-White
Stability
Hygroscopic
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(O)CCN(C)CCCCC
CAS DataBase Reference
114084 · 114084-78-5(CAS DataBase Reference)
FDA UNII
7 G2653W · UMD7G2653W
ATC code
5 BA06 · M05BA06
EPA Substance Registry System
1 · Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis- (114084-78-5)
Protein binding
87 % · 87%
Excreted unchanged in urine
50 · 50-60%
Volume of distribution
90 Litres · 90 Litres
Biological half-life
10 · 10-72 / Insignificantly increased1
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P305+P351+P338
Signs and Symptoms
LD<sub>50</sub> = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

ibandronate

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub> = 811 mg/kg (rat, oral)

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P305+P351+P338

Ibanronate is not metabolized in humans.

No evidence of ibandronate being metabolized in humans. Route of Elimination: Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces. Half Life: 10-60 hours

FDA Pharmacological Classification · 5 items

UMD7G2653W

IBANDRONIC ACID

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Ibandronic acid is a Bisphosphonate.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 4 items

Oral ibandronate is 0.63% bioavailable. In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL. The Tmax is approximately 1 hour, while Cmax varies depending on dose. A 2mg intravenous dose of ibandronate has an AUC of 316ng\*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng\*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng\*h/mL.

Ibandronate is predominantly eliminated in the urine and the unabsorbed drug is eliminated unchanged in the feces.

The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.

The total clearance of ibandronate is 84-160mL/min.

Cellular LocationsCytoplasm
Metabolite PathwaysIbandronate Action Pathway

Uses & manufacturing

Uses · 2 items

Use (kg; approx.) in Germany (2009): >100

For the treatment and prevention of osteoporosis in postmenopausal women.

Applications · 5 items

DescriptionThis third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.

UsesLabelled Ibandronic Acid (I120000). A bisphosphonate antiresorptive agent. Bone resorption inhibitor.

UsesA bisphosphonate antiresorptive agent. Bone resorption inhibitor.

UsesA biphosphonate bone resorption inhibitor.

UsesA labeled biphosphonate bone resorption inhibitor.

Upstream & downstream products

Downstream products

Ibandronate sodium monohydrate